Gabapentin and Acamprosate Co-Prescription Guidelines

Introduction to Safe Co-Prescription

• The American Geriatrics Society recommends against combining opioids with gabapentinoids, but does not warn against combining gabapentinoids with acamprosate, indicating no direct contraindication exists for their co-prescription 1.

Pharmacological Compatibility

• Acamprosate, which undergoes no hepatic metabolism and has no reported hepatotoxicity, is compatible with gabapentinoids, according to the French Association for the Study of the Liver guidelines 4.
• The French Association for the Study of the Liver guidelines discuss multiple pharmacological agents for alcohol dependence without mentioning any contraindication between gabapentin and acamprosate, supporting their safe co-use 4.

Clinical Considerations for Combined Use

• The American Geriatrics Society Beers Criteria does not list any interaction between gabapentinoids and acamprosate, allowing for their combined use in patients with alcohol use disorder 1.
• Acamprosate should be initiated 3-7 days after last alcohol consumption and only after withdrawal symptoms resolve, regardless of gabapentin use, as per standard clinical guidelines 2.

Dosing and Administration

• Acamprosate dosing remains standard at 666 mg three times daily for patients ≥60 kg, with gabapentin dosed according to its indication, ensuring no adjustment is needed for co-prescription 2.

Potential Therapeutic Synergy

• Acamprosate's side effect profile, which includes gastrointestinal effects like diarrhea, does not significantly overlap with gabapentin's side effects, reducing the risk of cumulative adverse events 3.